Annexon, Inc.
Clinical trials sponsored by Annexon, Inc., explained in plain language.
Annexon, Inc.
ANNX
NASDAQ
Develops complement-based therapies for autoimmune and neurodegenerative diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New eye injection aims to stop vision loss in dry AMD patients Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New hope for GBS: Single-Dose drug enters final testing Results expected Dec 2026 (estimated) 🚀 Make-or-break